MoonLake (MLTX) | Financial Analysis & Statements
MoonLake Immunotherapeutics Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-65.2M
Net Income
-63.0M
Balance Sheet Metrics
Total Assets
424.4M
Total Liabilities
120.0M
Shareholders Equity
304.5M
Debt to Equity
0.39
Cash Flow Metrics
Operating Cash Flow
-60.0M
Free Cash Flow
-58.8M
Revenue & Profitability Trend
MoonLake Income Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - |
| Gross Profit | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | ||||
| Research & Development | 202.9M | 112.8M | 31.8M | 42.0M |
| Selling, General & Administrative | 42.0M | 30.3M | 22.3M | 23.0M |
| Other Operating Expenses | - | - | - | - |
| Total Operating Expenses | 244.8M | 143.1M | 54.1M | 65.1M |
| Operating Income | -244.8M | -143.1M | -54.1M | -65.1M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | ||||
| Interest Income | - | - | - | - |
| Interest Expense | 7.2M | - | - | - |
| Other Non-Operating Income | 22.4M | 22.1M | 10.1M | 591.7K |
| Pre-tax Income | -229.7M | -121.0M | -44.0M | -64.5M |
| Income Tax | 611.0K | 282.2K | 94.4K | 36.4K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -230.3M | -121.2M | -44.1M | -64.5M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | ||||
| EBITDA | -219.8M | -141.7M | -54.1M | -65.0M |
| EPS (Basic) | $-3.53 | $-1.89 | $-0.73 | $-1.70 |
| EPS (Diluted) | $-3.53 | $-1.89 | $-0.73 | $-1.70 |
| Basic Shares Outstanding | 64463889 | 62870237 | 49122534 | 29361353 |
| Diluted Shares Outstanding | 64463889 | 62870237 | 49122534 | 29361353 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
MoonLake Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 334.5M | 180.4M | 451.2M | 39.5M | 8.0M |
| Short-term Investments | 59.5M | 267.6M | 59.8M | 32.6M | 0 |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 421.7M | 474.3M | 514.2M | 76.5M | 9.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 577.0K | 722.2K | 3.9M | 332.0K | 45.7K |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 596.0K | - | - | - | - |
| Total Non-Current Assets | 2.7M | 3.6M | 12.4M | 332.0K | 45.7K |
| Total Assets | 424.4M | 477.9M | 526.5M | 76.8M | 9.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 28.4M | 8.7M | 553.5K | 66.0K | 1.2M |
| Short-term Debt | 1.2M | 1.4M | 1.3M | 153.6K | 15.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 45.5M | 22.5M | 10.0M | 7.7M | 21.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 74.5M | 1.5M | 2.5M | 129.0K | 0 |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 74.5M | 2.1M | 3.1M | 411.2K | 239.9K |
| Total Liabilities | 120.0M | 24.5M | 13.0M | 8.1M | 21.3M |
| Equity | |||||
| Common Stock | 7.0K | 6.4K | 6.3K | 5.3K | 38.5K |
| Retained Earnings | -462.9M | -235.6M | -116.7M | -80.7M | -53.6M |
| Treasury Stock | - | - | - | 0 | 6.2K |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 304.5M | 453.4M | 513.5M | 68.8M | -11.6M |
| Key Metrics | |||||
| Total Debt | 75.7M | 2.8M | 3.8M | 282.6K | 15.0M |
| Working Capital | 376.2M | 451.8M | 504.2M | 68.8M | -11.5M |
Balance Sheet Composition
MoonLake Cash Flow Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -230.3M | -121.2M | -44.1M | -64.5M |
| Depreciation & Amortization | 2.6M | 1.4M | 13.2K | 12.4K |
| Stock-Based Compensation | 12.9M | 7.3M | 7.1M | 9.7M |
| Working Capital Changes | -3.8M | -3.2M | -1.2M | -220.8K |
| Operating Cash Flow | -219.7M | -116.0M | -37.7M | -54.8M |
| Investing Activities | ||||
| Capital Expenditures | -35.0K | -519.5K | -284.6K | -16.0K |
| Acquisitions | - | - | - | - |
| Investment Purchases | -265.4M | -350.3M | -175.7M | -42.2M |
| Investment Sales | 468.4M | 145.2M | 150.8M | 9.9M |
| Investing Cash Flow | 203.0M | -205.6M | -25.2M | -32.3M |
| Financing Activities | ||||
| Share Repurchases | - | -50 | - | 0 |
| Dividends Paid | - | - | - | - |
| Debt Issuance | 73.0M | - | - | - |
| Debt Repayment | - | 0 | 0 | -15.0M |
| Financing Cash Flow | 145.4M | 51.1M | 479.7M | 119.7M |
| Free Cash Flow | -196.0M | -117.1M | -43.1M | -55.9M |
| Net Change in Cash | 128.7M | -270.5M | 416.8M | 32.5M |
Cash Flow Trend
MoonLake Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-4.80
Forward P/E
-4.67
Price to Book
3.97
PEG Ratio
-4.67
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-60.78%
Return on Assets
-33.92%
Financial Health
Current Ratio
9.27
Debt to Equity
24.87
Beta
1.19
Per Share Data
EPS (TTM)
$-3.53
Book Value per Share
$4.27
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MLTX | 1.2B | -4.80 | 3.97 | -60.78% | 0.00% | 24.87 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






